Illumina Completes Deal for Grail Despite FTC Antitrust Challenge

Illumina said it wrapped up the $7.1 billion acquisition of life-sciences firm Grail, despite a legal battle with the Federal Trade Commission and antitrust concerns in Europe.

Post a Comment

Previous Post Next Post